Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Specialist ophthalmology appointments often present major geographic and scheduling hurdles for cancer patients requiring routine toxicity monitoring. Clinicians emphasize that optometrists can reliably perform baseline screenings and initial symptom checks, escalating only severe cases to ophthalmologists.

Related Insights

Given that access to ophthalmologists can be a significant bottleneck for patients, it is acceptable and practical for routine monitoring of mirvetuximab-related ocular side effects to be managed by optometrists. This pragmatic approach improves accessibility while ensuring patient safety.

While the antibody-drug conjugate (ADC) Tivdac offers a new treatment avenue, it introduces significant logistical hurdles. The requirement for a specialist eye exam at every single visit creates a major access barrier for clinics without integrated ophthalmology services, highlighting how non-clinical factors can limit the real-world application of effective drugs.

For ovarian cancer patients experiencing significant ocular side effects from the ADC mervituximab, switching the dosing schedule from every three weeks to every four weeks can resolve the toxicity by allowing an extra week for recovery.

GYN oncology nurses are accustomed to GI and hematologic side effects. With mirvetuximab, they must now manage eye-related issues, requiring patient education on prophylactic eye drops and coordination with ophthalmologists for regular exams.

For required ocular monitoring with certain ADCs, patients do not need to see a specialist ophthalmologist. An optometrist, including those at accessible and lower-cost retail locations, is fully qualified to perform the necessary exams. This practical tip helps mitigate financial toxicity and improves patient access to care.

Integrating next-gen SCLC treatments like T-cell engagers requires more than education; it demands a physical and operational overhaul. Community practices must build infrastructure for 24-hour observation and establish proactive partnerships with specialists like ophthalmologists to manage novel toxicities.

When managing ocular toxicity from the ADC mirvetuximab, clinicians advocate for delaying the subsequent dose to allow the cornea to heal naturally. This approach is often preferred over an immediate dose reduction, which might unnecessarily compromise the treatment's efficacy.

The ratio of patients to optometrists is worsening dramatically, projected to shift from 1:5000 today to 1:8000 in a decade. This widening provider gap, driven by a declining pipeline of new doctors, makes automated solutions like iBot's vision testing kiosk a necessity, not just a convenience.

A major logistical barrier to using belantamab is the required ophthalmic monitoring. However, these exams don't require a specialist ophthalmologist. Routine tests can be performed by a community optometrist, making the drug more accessible for patients and providers outside of large academic centers and lowering adoption barriers.

For managing the ocular toxicity associated with the ADC mirvetuximab, an optometrist is a sufficient and often more accessible alternative to an ophthalmologist. This practical insight simplifies care logistics for patients and oncology practices, improving access to necessary monitoring.

Substitute Optometrists for Ophthalmologists to Overcome Bottlenecks in Ocular ADC Screening | RiffOn